Sponsored by
The Musella Foundation attended the Society for Neuro-Oncology (SNO) Annual Meeting this past week. We're working on a comprehensive summary of highlights which will be shared soon, but in the meantime, we wanted to call attention to an important abstract on a Phase 1 trial of 12 newly diagnosed glioblastoma patients treated with a personalized neoantigen vaccine alongside the standard of care, including tumor treating fields. The results are remarkable: 100% progression-free survival at six months, 67% 2-year survival, and 58% 3-year survival. However, one patient experienced serious adverse events which ultimately led to brain demyelination and death. We really hope to see continuation and expansion of this research, not only for the exciting survival results, but also to gain a better understanding of this potential safety concern for personalized neoantigen vaccines (i.e., unintended T-cell cross-reactivity, potentially contributing to brain demyelination in one patient).